Loading
Expression Therapeutics
Expression Therapeutics, near Atlanta, makes cell and gene therapies. In cancer it programmes a patient's gamma-delta T cells to release a protein that pulls other immune cells onto the tumour, starting with neuroendocrine tumours.
Also called: Expression Therapeutics, Inc.
Overview
Expression Therapeutics, Inc., headquartered in Tucker, Georgia, with manufacturing in West Chester Township, Ohio, develops gene therapies for haemophilia A and cell therapies for cancer. Its ADEPT-STAR approach expands a patient's own gamma-delta T cells and programmes them with its LENTeT gene transfer system to secrete a T-cell engager. The lead, ADEPT-STAR-NET-1, secretes a CD3 by SSTR2 bispecific engager for gastroenteropancreatic neuroendocrine tumours and is preclinical. A 2026 National Cancer Institute SBIR award funds ADEPT-STAR therapy for high-risk neuroblastoma.
Headquarters
Tucker, GA, US
Scorecard
All companies#678of 1706 companies, score 4
- targets +2
- modalities +2
0 approved, 0 in phase 3, 0 earlier, 1 targets, 0 registry studies. Formula on the scorecards page.
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Grant · NCI SBIR (R44) award 2R44CA281633-02A1: ADEPT-STAR therapy for high risk neuroblastoma | 2026 | $1M | reporter.nih.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Products
1PreclinicalEngineered autologous gamma-delta T-cell therapy secreting a T-cell engager
ADEPT-STAR-NET-1 is an experimental cell therapy from Expression Therapeutics for neuroendocrine tumours. It has not yet been tested in people.
Notes
- Company website (home and neuroendocrine tumour pages) and the NIH RePORTER record read on 4 November 2026. The target used for neuroblastoma is not stated in the parts of the award read.
Connected
8Similar pages
- CompanyCaptor Therapeutics
- CompanyMabswitch
Shares Neuroblastoma (paediatric), T-cell engagers (bispecific).
- TargetTryptophan hydroxylase 1
- CompanyNuclearMediX
- CompanyNuclidium
- TreatmentLutetium Lu 177 dotatate (PNT2003)
- PersonMartyn E. Caplin
- PersonSimron Singh
cancers
fronts
technologies
targets
drugs
PreclinicalEngineered autologous gamma-delta T-cell therapy secreting a T-cell engager
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
expressiontherapeutics.com · 2
nih.gov · 1
A source that has moved or gone is reported by the weekly link check. /audit/